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Background: In rats, it has been observed that treatment with activators of peroxisome proliferator-activated
receptor α (PPARα) disturbs metabolic adaptations during lactation, which in turn lead to a reduction of milk fat
content and gains of litters during the suckling period. It has not yet been investigated whether agonists of PPARα
are impairing milk production of lactating sows in a similar manner as in rats. Therefore, the present study aimed to
investigate the effect of treatment with clofibrate, a strong synthetic agonist of PPARα, on milk composition and
litter gains in lactating sows.
Results: Twenty lactating sows received either a basal diet (control group) or the same diet with supplementation
of 2 g of clofibrate per kg of diet (clofibrate group). In the clofibrate group, mRNA concentrations of various PPARα
target genes involved in fatty acid utilization in liver and skeletal muscle were moderately up-regulated. Fat and
energy content of the milk and gains of litters during the suckling period were not different between the control
group and the clofibrate group.
Conclusion: It is shown that treatment with clofibrate induces only a moderate up-regulation of PPARα target
genes in liver and muscle of lactating sows and in turn might have limited effect on whole body fatty acid
utilization. This may be the reason why clofibrate treatment did not influence milk fat content and gains of litters
during the suckling period. Thus, the present study indicates that activation of PPARα induced either by native
agonists such as dietary polyunsaturated fatty acids or a by negative energy balance might be largely uncritical in
lactating sows with respect to milk production and litter gains in lactating sows.Background
Lactation is a physiological state which in most animal
species is associated with a strong increase in energy
and nutrient requirement for milk production. This de-
mand is usually met by marked increase in feed intake
and by utilization of body’s energy stores. In some ani-
mal species such as rats or mice, additionally metabolic
adaptations occur during lactation which aim to con-
serve energy for milk production [1-3]. Down-regulation
of proteins involved in fatty acid uptake and oxidation in
liver and skeletal muscle and a decreased thermogenesis
contribute to these energy sparing effects [3-6]. We have* Correspondence: klaus.eder@ernaehrung.uni-giessen.de
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unless otherwise stated.observed that these effects in lactating rodents are medi-
ated by a suppression of peroxisome proliferator-activated
receptor α (PPARα), a transcription factor which controls
the expression of many genes involved in lipid catabolism
[7,8]. In lactating rats, it has been moreover observed that
an activation of PPARα by feeding an oxidized fat causes a
disturbance of those metabolic adaptations. It has been
found that there was an increased uptake of fatty acids
into the liver and an increased oxidation of fatty acids in
the lactating rats fed the oxidized fat, which in turn led to
a reduced availability of fatty acids for milk production,
resulting in a reduced milk triacylglycerol (TAG) concen-
tration and reduced growth rates of the suckling pups [9].
In lactating sows, milk production is important for the
post-natal growth of their litters. However, in contrast to
rodents, the role of PPARα in lactating sows has not yetl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion of PPARα during lactation could suppress milk fat
synthesis due to a reduced availability of fatty acids as a
result of an increased utilization of fatty acids by liver
and muscle. The question whether activation of PPARα
could affect milk fat synthesis is of relevance as dietary
components such as polyunsaturated fatty acids (PUFA)
are able to activate PPARα [10-12]. Moreover, it is
known that a negative energy balance which is common
in lactating sows causes an activation of PPARα due to
increased concentrations of NEFA in plasma released
from adipose tissue [13-15]. Indeed, recently an activa-
tion of PPARα in liver of lactating sows with a negative
energy balance has been observed [16-18]. However,
metabolic effects of activation of PPARα in lactating
sows have not been investigated so far. In order to inves-
tigate the hypothesis that activation of PPARα could im-
pair milk production, we performed an experiment with
lactating sows which were fed a diet supplemented with
clofibrate as a synthetic agonist of PPARα and deter-
mined milk composition and gains of litters.
Methods
Animals and diets
Twenty second parity sows (Large White and German
Landrace) were artificially inseminated and kept in single
crates until day 21 of pregnancy. From day 21 to 110 of
pregnancy, the sows were kept in groups in pens
equipped with fully slatted floors, nipple drinkers and
feeders with a temperature of 19 ± 1°C with a 12:12 h
light–dark cycle and 60–80% relative humidity by means
of an air conditioning system. On day 110 of pregnancy,
they were housed individually in farrowing crates. After
parturition, the sows were randomly assigned into two
feeding groups of 10 animals each with an equalized lit-
ter size of 8 piglets per sow. Infrared heaters were used
to provide a surrounding temperature of 35°C for new-
born pigs. The duration of the suckling period was
21 days.
During lactation all sows were fed a nutritionally ad-
equate basal diet consisting mainly of (in g/kg diet):
wheat (325), barley (400), soybean meal with 43% crude
protein (190), a mixture of soybean oil and palm oil (50)
(1:4, w/w) and a mineral supplement (35) (Sauengold Lac®,
Sano-Moderne Tierernährung GmbH, Loiching, Germany).
The basal diet contained 13.8 MJ metabolizable energy
(ME)/kg; concentrations of crude nutrients were (g/kg
diet): Crude protein, 154; crude fat, 74; crude fiber, 45;
crude ash, 43; starch, 395. Major fatty acids of the basal
diet were (g/100 g of total fatty acids): Palmitic acid (16:0),
31.5; stearic acid (18:0), 3.9; oleic acid (18:1), 30.7; linoleic
acid (18:2 n-6), 29.4; α-linolenic acid (18:3 n-3) 2.0. The
control group received the basal diet without any further
supplement. The second group (“clofibrate group”)received the basal diet supplemented with 2 g of clofibrate
(Sigma-Aldrich, Schnelldorf, Germany) per kg of diet. At
the day of parturition, the sows were given 3 kg of the diet.
From day 2 of lactation to later lactation, the amount of
diet administered was calculated in order to meet the en-
ergy requirement of the sows (assuming daily litter gains
of 2 kg) [19]. Water was given ad libitum by nipple
drinkers. Feed intakes were recorded daily and body
weights weekly. The energy balance of the sows during
lactation was estimated as the difference of ME intake and
total energy requirement for maintenance and energy re-
quirement for milk production. It was assumed that milk
production for 1 kg of litter gain is equivalent to an energy
demand of 29.3 MJ ME [19]. The piglets were offered a
creep feed (Bonni M-Forte, Sano-Moderne Tierernährung)
from day 15 until weaning.
All experimental procedures were carried out in accord-
ance with established guidelines for the care and handling
of laboratory animals and were approved by the local
Animal Welfare Authorities (Regierungspräsidium Giessen;
permission no: GI 19/3-No. 29/2010).Sample collection
On day 20 of lactation, blood from Vena jugularis was col-
lected 3 h after feed intake into heparinized polyethylene
tubes (Sarstedt, Nürnberg, Germany) and plasma was
subsequently obtained by centrifugation of the blood
(1100 × g, 10 min, 4°C) and stored at −20°C. On day 20,
liver and muscle biopsy samples were taken percutan-
eously after anaesthesia by intramuscular injection of 2
mg azaperon (Stresnil, Janssen, Germany) per kg body
mass, 20 mg ketamine (Ursotamin, Serumwerke Bernburg
AG, Germany) per kg body mass and up to 2.4 mg
thiopental (Thiopental 0.5 g, Inresa, Freiburg, Germany)
per kg body mass as required for maintenance of anaesthe-
sia. The pigs were placed in the left lateral recumbency and
the surgical area was infiltrated with 1 mL of 2% lidocaine
hydrochloride (BelaPharm, Vechta, Germany) for local an-
aesthesia. A percutaneous liver biopsy was performed with
a 16 G/1.65 mm biopsy needle (length: 160 mm) on a His-
toCore® system (BIP Biomed. Instrumente & Produkte
GmbH, Türkenfeld, Germany) on expected anatomical lo-
cation of the liver under constant ultrasound guidance.
The intramuscular biopsy (M. longissimus dorsi) was per-
formed with a spirotome (8 G, Medinvents, Hasselt,
Belgium). After removal of the samples, the sites for biopsy
were subsequently closed with synthetic absorbable surgi-
cal suture. For collection of milk samples, sows were given
20 I.U. oxytocin (CP-Pharma, Burgdorf, Germany) by
intramuscular injection. 80–100 ml of milk was expressed
manually from all active teats of each sow. Liver and
muscle samples were stored at −80°C and milk samples
were stored at −20°C pending analysis.
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Measurements of protein and fat concentrations in the
milk were performed by the official methods of Verband
Deutscher Landwirtschaftlicher Untersuchungs- und
Forschungsanstalten (VDLUFA) [20]. The concentration
of lactose in the milk was determined using a commer-
cial kit (cat. no. 10986119035, R-Biopharm, Darmstadt,
Germany) according to the manufacturer’s instructions.
The gross energy content of the milk was calculated
using the following gross energy values: fat = 39 kJ/g,
protein = 24 kJ/g, lactose = 17 kJ/g. For analysis of the
fatty acid composition of milk total lipids, lipids were ex-
tracted from the milk with a hexane:isopropanol (3:2, v/v)
mixture [21]. Fatty acids were analyzed by capillary gas
chromatography after converting fatty acids into their me-
thyl esters by trimethyl sulfonium hydroxide [22]. Concen-
trations of retinol and α-tocopherol in milk samples were
determined by HPLC (L-7100, LaChrom, Merck-Hitachi,
Darmstadt, Germany) using a modification of the method
of Balz et al. [23]. Samples of 0.5 ml of milk were mixed
with 2 ml of a 10 g/l pyrogallol solution (in ethanol, abso-
lute) and 300 μl of a saturated sodium hydroxide solution.
After flushing with nitrogen, this mixture was heated for
30 min at 70°C in closed glass tubes. Retinol and α-
tocopherol were then extracted by addition of 2 ml of n-
hexane and 2 ml of bidest. water. After centrifugation, an
aliquot of the hexane phase was evaporated to dryness
under nitrogen and re-dissolved in methanol containing
0.05% of butylated hydroxytoluene. Retinol and α-
tocopherol were separated isocratically by HPLC using
a mixture of methanol and water (96:4, v/v) as mobile
phase and a LiChrosher 100 RP18 column (5 μm par-
ticle size, 125 mm length, 4.6 mm internal diameter,
Merck, Darmstadt, Germany) and detected by fluorescence
(Fluorescence Detector L-7480, LaChrom, Merck-Hitachi,
Darmstadt, Germany; retinol: excitation wavelength,
325 nm, emission wavelength, 475 nm; α-tocopherol: exci-
tation wavelength, 295 nm, emission wavelength, 325 nm).
Concentration of TAG and NEFA in plasma
Plasma concentrations of TAG and NEFA were mea-
sured using enzymatic kits [Fluitest® TG, Cat. No. 5741,
Analyticon® Biotechnologies AG, Lichtenfels, Germany;
NEFA-HR (2), Code No. 436–91995, Wako Chemicals
GmbH, Neuss, Germany].
RNA isolation and qPCR
RNA isolation from frozen liver and muscle biopsies and
quantitative real-time PCR (qPCR) analysis were per-
formed as described recently in detail [24]. In brief, total
RNA from frozen liver and muscle samples was isolated
using Trizol® Reagent (Invitrogen, Karlsruhe, Germany)
according to the manufacturer’s protocol and purified
using the RNeasy Minikit (Qiagen, Hilden, Germany).Concentration and purity of the RNA were estimated
from the optical density at 260 and 280 nm, respectively.
The integrity of total RNA was verified using 1.2% agar-
ose gel electrophoresis. cDNA was synthesized using
1.2 μg of total RNA, 100 pmol oligo(dT)18 primer
(Eurofins MWG Operon, Ebersberg, Germany), 1.25 μl
10 mM dNTP mix (GeneCraft, Lüdinghausen,
Germany), 5 μl 5x RT reaction buffer (Thermo Fisher
Scientific, St. Leon-Rot, Deutschland), and 60 units M-
MuLV Reverse Transcriptase (Thermo Fisher Scientific)
at 42°C for 60 min and a final inactivating step at 70°C
for 10 min in a thermo cycler (Biometra, Göttingen,
Germany). qPCR runs were performed with a Rotorgene
2000 system (Corbett Research, Mortlake, Australia)
using KAPA SYBR FAST qPCR Universal Mastermix
(Peqlab, Erlangen, Germany) and gene-specific primer
pairs from Eurofins MWG Operon (Ebersberg, Germany).
Ct-values of target and reference genes were obtained using
Rotorgene Software 5.0. Determination of relative expres-
sion levels was calculated using GeNorm normalization fac-
tor including the three most stable out of six reference
genes [25]. Gene-specific primer pairs were designed
intron-spanning if possible using Primer3 and BLAST.
Characteristics of primers used for qPCR analysis are
shown in Table 1.
Statistical analysis
Statistical analysis was performed by student’s t test
using the Minitab Statistical Software Rel. 13.0 (Minitab,
State College, PA, USA). Differences were considered
statistically significant for P < 0.05.
Results
Daily feed intake, body weights and energy balance of
the lactating sows
The daily feed intake during the three weeks of lactation
was not different between control sows and sows admin-
istered clofibrate (Table 2). Body weights of the sows at
day 1 post partum and day 21 post partum and body
weight losses of the sows from day 1 to day 21 were
similar in both groups of sows (Table 2). The calculated
energy balance of the sows from day 1 post partum to
day 14 post partum, the time period in which piglets did
not receive any additional feed, was also similar in both
groups of sows (Table 2).
mRNA concentrations of PPARα target genes in tissues of
the lactating sows
In overall, administration of clofibrate had only a moder-
ate effect on the expression of the PPARα target genes in
liver and muscle of sows on day 20 of lactation (Table 3).
In the liver, mRNA concentrations of only 2 out of the 7
PPARα target genes considered (CPT1A and CYP4A24)
were significantly up-regulated by administration of
Table 1 Characteristics of gene specific primers used for qPCR
Gene Forward primer (from 5′ to 3′) PCR product
size (bp)
NCBI GenBank Slope R2 Efficiency M-value
Reverse primer (from 5′ to 3′)
Reference genes
ACTB GACATCCGCAAGGACCTCTA 205 XM_003124280.3 −3.76 1.000 0.84 0.034
ACATCTGCTGGAAGGTGGAC
ATP5G1 CAGTCACCTTGAGCCGGGCGA 94 NM_001025218.2 −3.43 0.999 0.99 0.033
TAGCGCCCCGGTGGTTTGC
GSR AGCGCGATGCCTACGTGAGC 175 XM_003483635.2 −3.43 0.997 0.96 0.038
GGTACGCCGCCTGTGGCAAT
RPS9 GTCGCAAGACTTATGTGACC 325 XM_005664825.1 −3.78 0.999 0.84 0.034
AGCTTGAAGACCTGGGTCTG
PPARα target genes
ACOX1 CTCGCAGACCCAGATGAAAT 218 NM_001101028.1 −3.53 0.999 0.92
TCCAAGCCTCGAAGATGAGT
CD36 TCCTCTGACATTTGCAGGTCAATCT 107 NM_001044622.1 −3.59 0.999 0.90
GGAGATGCAAAAGCTGTGGATGG
CPT1A GCATTTGTCCCATCTTTCGT 198 NM_001129805.1 −3.46 0.999 0.95
GCACTGGTCCTTCTGGGATA
CPT1B CACACTGCAGCACCTCACA 183 NM_001007191.1 −4.09 1.000 0.76
GTGAGGGCTGCCAGCTTTT
CYP4A24 GGTTTGCTCCTGTTGAATGG 121 NM_214424.1 −3.34 1.000 0.99
GCATCACTTGGACAGACTTG
FABP1 ATCGTGCAGAATGGGAAGCA 133 NM_001004046.1 −3.43 0.999 0.96
ACTGAACCACTGTCTTGACC
FABP3 CAACATGACCAAGCCTACCA 227 NM_001099931.1 −3.36 1.000 0.98
CTAGTTCCCGAACAAGCGTT
LPL TTCTCCCGACGACGCAGATTTT 166 NM_214286.1 −3.36 0.988 0.98
TGCAATCACACGGATGGCTTCT
SLC27A1 GGTTCCAGCCTGTTGAATGT 275 NM_001083931.1 −3.38 0.992 0.98
AACAAAACCTTGGTGCTTGG
UCP3 GCCACTTTGTCTCTGCCTTC 219 NM_214049.1 −3.39 1.000 0.97
CAAACATCACCACGTTCCAG
Genes of the ubiquitin proteasome system
FBXO32 TCACAGCTCACATCCCTGAG 167 NM_001044588.1 −3.30 0.994 1.01
GACTTGCCGACTCTCTGGAC
TRIM63 ATGGAGAACCTGGAGAAGCA 219 NM_001184756.1 −3.62 0.998 0.89
ACGGTCCATGATCACCTCAT
UBB GGTGGCTGCTAATTCTCCAG 127 NM_001105309.1 −3.51 1.000 0.93
TTTTGGACAGGTTCAGCTATTAC
Abbreviations: ACOX1 acyl-CoA oxidase, ACTB actin, beta, ATP5G1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1, CD36 fatty acid translocase,
CPT1 carnitine-palmitoyl-transferase, CYP4A24 cytochrome P450 A24, FABP fatty acid binding protein, FBXO32 F-box protein 32, LPL lipoprotein lipase, GSR
glutathione reductase, PPARα peroxisome proliferator- activated receptor α, RPS9 ribosomal protein S9, SLC27A1 solute carrier family 27 (fatty acid transporter),
member 1, TRIM63 tripartite motif containing 63, E3 ubiquitin protein ligase, UBB ubiquitin B, UCP3 uncoupling protein 3.
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regulation for these genes, with the only exception of
CPT1A was moderate. In muscle, there was a significant(P < 0.05) up-regulation of 5 out of the 8 PPARα target
genes considered (ACO, CD36, CPT1B, CYP4A24, LPL).
As in the liver, the extent of up-regulation of these
Table 2 Daily feed intake, body weights and energy balance
of lactating control sows and sows administered clofibrate
Control Clofibrate P-value
Daily feed intake (kg/d)
Week 1 6.06 ± 0.65 5.47 ± 0.75 0.088
Week 2 5.88 ± 0.91 6.26 ± 0.63 0.333
Week 3 6.29 ± 0.57 6.28 ± 0.97 0.978
Weeks 1–3 6.08 ± 0.54 6.00 ± 0.67 0.807
Body weight (kg)
Day 1 p.p. 264 ± 15.4 263 ± 18.3 0.910
Day 21 p.p. 247 ± 21.0 242 ± 27.9 0.688
Body weight loss (kg)
Day 1 p.p. – day 21 p.p. 16.9 ± 9.14 20.9 ± 16.42 0.550
Energy balance (MJ ME/d),
Day 1 p.p. – day 14 p.p. −4.91 ± 13.25 −9.24 ± 8.88 0.436
Values are mean ± SD (n = 10/group); p.p. = post partum.
Table 4 Concentrations of TAG and NEFA in plasma of
lactating control sows and sows administered clofibrate
on day 20 of lactation
Control Clofibrate P-value
TAG (mmol/L) 0.37 ± 0.13 0.23 ± 0.09 0.029
NEFA (μmol/L) 152 ± 66 64 ± 18 0.002
Values are mean ± SD (n = 10/group).
Gessner et al. BMC Veterinary Research  (2015) 11:54 Page 5 of 8genes, being in the range between 43% and 68%, how-
ever, was relatively moderate (Table 3).Table 5 Composition of milk of lactating control sows
and sows administered clofibrate on day 20 of lactationConcentrations of TAG and NEFA in plasma
The concentrations of TAG and NEFA in plasma on day
20 of lactation were significantly lower in the clofibrate
group than in the control group (P < 0.05, Table 4).Table 3 Relative mRNA concentrations of PPARα target
genes in liver and muscle of lactating control sows and
sows administered clofibrate on day 20 of lactation
Control Clofibrate P-value
Liver
ACOX1 1.00 ± 0.61 1.16 ± 0.65 0.577
CD36 1.00 ± 0.38 0.91 ± 0.39 0.656
CPT1A 1.00 ± 0.75 3.86 ± 1.77 0.003
CYP4A24 1.00 ± 0.47 1.66 ± 0.57 0.034
FABP1 1.00 ± 0.36 1.32 ± 0.42 0.144
LPL 1.00 ± 0.49 1.48 ± 0.48 0.104
SLC27A1 1.00 ± 0.47 0.96 ± 0.14 0.835
Muscle
ACO 1.00 ± 0.36 1.62 ± 0.38 0.002
CD36 1.00 ± 0.16 1.43 ± 0.16 < 0.001
CPT1B 1.00 ± 0.37 1.64 ± 0.53 0.001
CYP4A24 1.00 ± 0.38 1.52 ± 0.31 0.012
FABP3 1.00 ± 0.24 1.27 ± 0.35 0.094
LPL 1.00 ± 0.51 1.68 ± 0.48 0.010
SLC27A1 1.00 ± 0.10 1.12 ± 0.14 0.101
UCP3 1.00 ± 0.32 1.16 ± 0.20 0.296
Values are mean ± SD (n = 10/group); Abbreviations: see Footnote of Table 1.Milk composition of the lactating sows and gains of litters
Concentrations of fat, lactose and the calculated gross
energy content of the milk on day 20 of lactation did not
differ between control sows and sows administered clofi-
brate. However, the concentration of protein in the milk
was higher in the clofibrate group than in the control
group (Table 5). The fatty acid composition of milk total
lipids was slightly different between the two groups of
sows. In the milk of sows administered clofibrate, the
proportion of palmitic acid (16:0) was slightly higher and
proportions of linoleic acid (18:2 n-6) and α-linoleic acid
(18:3 n-3) were slightly lower than in milk of control
sows (Table 5). Proportions of all the other fatty acids in
milk total lipids were unchanged between the two
groups of sows (Table 5). According to the differences in
the proportions of palmitic acid, linoleic acid and α-Control Clofibrate P-value
Nutrients (%)
Fat 6.81 ± 0.49 6.92 ± 1.15 0.797
Lactose 4.85 ± 0.47 5.04 ± 0.42 0.367
Protein 5.19 ± 0.39 5.66 ± 0.33 0.012
Gross energy (MJ/kg)# 4.73 ± 0.22 4.91 ± 0.47 0.297
Fatty acids (% of total fatty acids)
14:0 4.5 ± 0.7 4.6 ± 0.6 0.856
16:0 27.1 ± 1.6 30.1 ± 2.0 0.006
16:1 n-9 12.4 ± 1.6 12.1 ± 1.0 0.658
18:0 2.9 ± 0.4 3.0 ± 0.4 0.360
18:1 n-9 31.7 ± 3.5 30.8 ± 3.1 0.570
18:1 n-7 1.9 ± 0.3 1.9 ± 0.2 0.819
18:2 n-6 15.2 ± 0.4 13.7 ± 0.7 < 0.001
18:3 n-3 1.2 ± 0.1 1.0 ± 0.1 0.018
Σ SFA 35.3 ± 2.1 38.5 ± 2.7 0.021
Σ MUFA 46.6 ± 2.6 45.3 ± 2.6 0.313
Σ PUFA 18.1 ± 0.7 16.3 ± 0.9 < 0.001
Fat soluble vitamins (nmol/g fat)
Retinol 16.1 ± 3.74 17.9 ± 4.46 0.374
α-tocopherol 83.4 ± 27.1 95.9 ± 24.1 0.314
Values are mean ± SD (n = 10/group); Abbreviations: SFA saturated fatty acids,
MUFAmonounsaturated fatty acids, PUFA polyunsaturated fatty acids.
#calculated value.
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higher proportion of total saturated fatty acids and a
lower proportion of total polyunsaturated fatty acids
(PUFA) than milk of control sows (Table 5). The con-
centrations of the fat soluble vitamins retinol and α-
tocopherol in the milk, expressed per g of fat, were also
similar in both groups of sows (Table 5). Gains of litters
during the first 14 days (the period in which piglets re-
ceived sows milk exclusively) and the whole 21 days
suckling period were also not different between control
sows and sows supplemented with clofibrate (Table 6).
Relative mRNA concentrations of components of the
ubiquitin proteasome system in muscle
In order to find out whether an enhanced proteolysis in
muscle could be the reason for an increase of milk protein
content found in sows treated with clofibrate, mRNA con-
centrations of UBB (encoding ubiquitin), FBOX32 (encod-
ing atrogin-1) and TRIM63 (encoding muscle specific
RING Finger protein 1, MuRF-1) in muscle were deter-
mined. Relative mRNA concentrations of these three
genes were higher in sows treated with clofibrate than in
control sows [control group vs. clofibrate group: UBB,
1.00 ± 0.23 vs. 1.28 ± 0.12 (P = 0.009); FBOX32, 1.00 ± 0.64
vs. 1.98 ± 0.80 (P = 0.025); TRIM63, 1.00 ± 0.45 vs. 2.71 ±
0.97 (P = 0.001); means ± SD for all genes].
Discussion
This study was performed to investigate the effect of ac-
tivation of PPARα on the expression of genes involved in
the utilization of fatty acids in liver and muscle of lactating
sows. Moreover, we aimed to find out whether alterations
in fatty acid utilization could affect milk fat synthesis. To
induce activation of PPARα, lactating sows were fed a diet
supplemented with clofibrate, a well-known synthetic
agonist of PPARα belonging to the group of fibrates [26].
We found that sows fed the diet supplemented with clofi-
brate indeed showed an up-regulation of several classical
PPARα target genes involved in fatty acid uptake and oxi-
dation in liver and muscle which in its extent, however,Table 6 Weights of litters from lactating control sows and
sows administered clofibrate at birth and gains of litters
during the period from day 1 to day 21 of lactation
Control Clofibrate P-value
Weights of litters (kg)
Day 1 12.5 ± 1.28 12.8 ± 1.58 0.657
Day 21 57.4 ± 6.09 58.9 ± 5.22 0.602
Gains of litters (kg)
Day 1 – day 14 28.0 ± 4.09 29.5 ± 3.96 0.448
Day 1 – day 21 45.0 ± 6.88 46.1 ± 5.25 0.704
Values are mean ± SD (n = 10/group). Litters were standardized to 8 piglets
per sow.was weaker than in previous studies with young pigs
treated with clofibrate [15,27,28]. The changes in mRNA
concentrations of PPARα target genes indicate that the
clofibrate treatment of the sows caused a moderate activa-
tion of PPARα in liver and muscle. The main reason for
the relatively weak up-regulation of PPARα target genes
might be that the dose of clofibrate given to the sows in
this study (2 g/kg diet, equivalent to 45 mg/kg body
weight) was lower than the doses given to young pigs in
the recent studies (5 g/kg diet, equivalent to doses of 300–
500 mg/kg body weight) [15,27,28]. Moreover, it should be
noted that pigs have generally a relatively low expression
of PPARα in comparison to some other species such as ro-
dents and target genes are less responsive against agonists
[15,27,29]. It has been shown in sows that a negative en-
ergy balance commonly observed during lactation could
induce activation of PPARα due to increased concentra-
tions of NEFA released from adipose tissue [16,17]. As the
control sows considered in this study had only a slight
negative energy balance which was reflected by low
plasma NEFA concentrations, it is unlikely that there was
a pronounced activation of PPARα in tissues of the control
sows. Moreover, it is unlikely that there was an activation
of PPARα by dietary fatty acids as the dietary fat, a mixture
of soybean oil and palmoil (1:4, w/w), provided low
amounts of highly unsaturated fatty acids with a high af-
finity to PPARα.
The finding that plasma TAG and NEFA concentra-
tions were reduced by clofibrate treatment suggests that
the moderate up-regulation of PPARα target genes led
to an increased utilization of TAG and fatty acids in tis-
sues. Reduced plasma TAG concentrations which have
been reported as a typical feature of activation of PPARα
in rats and pigs are mainly due to a reduced secretion of
lipid from the liver into the blood and an increased
clearance of plasma TAG by lipoprotein lipase (LPL)
[30,31]. As sows treated with clofibrate showed an up-
regulation of LPL in muscle, it is likely that the reduc-
tion of plasma TAG concentration was at least in part
due to an increased lipolysis. A reduction of plasma
NEFA concentration which has also been reported in
humans or animals treated with fibrates [32-35] might
be mainly due to the up-regulation of fatty acid trans-
porters which are direct targets of PPARα [14]. In the
present study, we observed an up-regulation of CD36,
one of the key fatty acid transporters, in muscle of sows
treated with clofibrate which might contribute to the re-
duction of plasma NEFA concentration observed in the
sows treated with clofibrate.
The finding that fat and energy content of the milk
and weight gains of litters during the suckling period (in-
cluding the first 14 days of suckling in which sows milk
was the only source of nutrients) were not different be-
tween the two groups of sows shows that the moderate
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by clofibrate did not cause an impairment of milk synthe-
sis in the mammary gland. Sows’ milk fat consists mainly
of two sources of fatty acids, namely those deriving from
de-novo fatty acid synthesis in the mammary gland and
those released from TAG-rich lipoproteins by LPL and
taken up into the mammary gland. In contrast, plasma
NEFA contribute less to the production of milk TAG as
the uptake of NEFA into the mammary gland is relatively
low in sows in comparison to other species such as cattle
[36]. Fatty acids deriving from de-novo synthesis are
mainly saturated and monounsaturated, while those trans-
ported via chylomicrons to the mammary gland are
reflecting the dietary fatty acid profile [36]. A reduced
plasma TAG concentration in sows treated with clofibrate
indicates that there was a lower availability of fatty acids
from TAG-rich lipoproteins in the mammary gland which
might provide an explanation for the finding that milk of
these sows had slightly lower concentrations of PUFA.
Nevertheless, this study shows that a moderate reduction
of plasma TAG concentration by administration of a
strong PPARα agonist does not impair milk fat synthesis.
An unexpected finding of this study was that sows
treated with clofibrate showed an increased protein con-
tent in the milk. As milk protein synthesis depends on
the availability of amino acids in the mammary gland
[36], an increased flux of amino acids via blood to the
mammary gland could provide a potential explanation
for this observation. Recently, we have observed that
treatment of rodents with clofibrate stimulates the ubi-
quitin proteasome system and enhances protein break-
down in muscle [37]. In the present study we observed
that treatment of sows with clofibrate causes an up-
regulation of ubiquitin and the two E3 ligases atrogin-1
and MuRF-1 which are-rate limiting for the ubiquitin
proteasome system. This finding suggests, although we
do not have direct evidence for this, that treatment with
clofibrate stimulates protein breakdown in muscle of
sows which in turn could increase the availability of
amino acids for milk protein synthesis. However, this re-
mains a matter of speculation. We moreover observed
that concentrations of retinol and α-tocopherol in the
milk were not different between the two groups indicat-
ing that clofibrate did not influence the metabolism of
fat soluble vitamins, i.e. their delivery from TAG-rich li-
poproteins into the mammary gland.
It has been established that dietary fatty acids such as
n-3 PUFA can act as agonists of PPARα [10-12]. Based
on the fact that the PPARα activating potential of those
fatty acids is lower than that of synthetic PPARα agonists
such as clofibrate, the findings of the present study
clearly indicate that fatty acids in sow diets acting as na-
tive PPARα agonists might be uncritical with respect to
milk production and gains of litters of lactating sows.The study moreover suggests that a moderate up-
regulation of PPARα target genes involved in fatty acid
uptake and oxidation in liver and muscle as a conse-
quence of a negative energy balance might not interfere
with milk production of sows. This suggestion is sup-
ported by the observation that lactating sows are able to
maintain their milk production even under the condition
of a negative energy balance as long as their body fat re-
serves are not depleted to a large extent [38].
Conclusions
In overall, the present study shows that treatment of lac-
tating sows with clofibrate, a strong synthetic PPARα
agonist, induces only a moderate activation of PPARα in
liver and muscle and in turn had limited effect on whole
body fatty acid utilization. This may be the reason why
clofibrate treatment did not influence milk composition
and gains of litters during the suckling period. Thus, the
present study indicates that activation of PPARα induced
either by native agonists such as dietary PUFA or a by
negative energy balance might be largely uncritical in
lactating sows with respect to milk production and litter
gains in lactating sows.
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